Sonia Tamanna

Sonia Tamanna

Auto-generated profile, based on publicly available information

Sonia Tamanna

Department of Biochemistry and Molecular Biology, University of Dhaka, Dhaka, Bangladesh

Research Focus & Metrics

Representative Publications

View All Publications
20 October 2021 in American Journal of Physiology-Regulatory, Integrative and Comparative Physiology
Verified
Journal Article
Closed access
PDF file
STSonia Tamanna
Sonia Tamanna
ELEugenie R. Lumbers
Eugenie R. Lumbers
SMSaije K. Morosin
Saije K. Morosin
SDSarah J. Delforce
Sarah J. Delforce
KPKirsty G Pringle
Kirsty G Pringle
Angiotensin-converting enzyme 2 (ACE2) is a membrane-bound protein containing 805 amino acids. ACE2 shows approximately 42% sequence similarity to somatic ACE but has different biochemical activities. The key role of ACE2 is to catalyze the vasoconstrictor peptide angiotensin (ANG) II to Ang-(1–7), thus regulating the two major counterbalancing pathways of the renin-angiotensin system (RAS). In this way, ACE2 plays a protective role in end-organ damage by protecting tissues from the proinflammatory actions of ANG II. The circulating RAS is activated in normal pregnancy and is essential for maintaining fluid and electrolyte homeostasis and blood pressure. Renin-angiotensin systems are also found in the conceptus. In this review, we summarize the current knowledge on the regulation and function of circulating and uteroplacental ACE2 in uncomplicated and complicated pregnancies, including those affected by preeclampsia and fetal growth restriction. Since ACE2 is the receptor for SARS-CoV-2, and COVID-19 in pregnancy is associated with more severe disease and increased risk of abnormal pregnancy outcomes, we also discuss the role of ACE2 in mediating some of these adverse consequences. We propose that dysregulation of ACE2 plays a critical role in the development of preeclampsia, fetal growth restriction, and COVID-19-associated pregnancy pathologies and suggest that human recombinant soluble ACE2 could be a novel therapeutic to treat and/or prevent these pregnancy complications.

14 March 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
INImrul Kayes Nabil
Imrul Kayes Nabil
ZMZimam Mahmud
Zimam Mahmud
STSonia Tamanna
Sonia Tamanna
MRMostafijur Rahman
Mostafijur Rahman
GRGowhar Rashid
Gowhar Rashid
ZHZakir Hossain Howlader
Zakir Hossain Howlader
Vitamin D receptor (VDR) gene is implicated in hypertension vulnerability due to its role in regulating the renin-angiotensin system (RAS) and blood pressure. In this case-control study, a carefully selected cohort of 111 hypertensive individuals and 100 healthy controls underwent serum analysis using HPLC to measure 25-hydroxy vitamin D levels. Polymorphic variations in the VDR gene were detected and characterized using the PCR-RFLP method. At first, lower 25-hydroxy vitamin D levels were observed in hypertensive individuals compared to controls (p0.05). Similarly, no significant difference was found in the VDR gene BsmI genotype frequency between hypertensive patients and controls (p>0.05). However, a statistically significant distinction was observed in the VDR gene FokI genotype frequency between cases and controls (p<0.01). The odds ratios for FokI genotypes (CC, CT, TT, and CT+TT) were 1.0, 0.590, 1.566, and 0.963, respectively. Furthermore, serum 25-hydroxy vitamin D levels were significantly higher in control subjects compared to hypertensive patients across all genotypes of VDR (p<0.001). Hypertensive patients, excluding those with the FokI VDR gene CC genotype, exhibited significantly higher systolic blood pressure levels compared to the control group (p<0.05). Similarly, hypertensive subjects displayed elevated diastolic blood pressure levels compared to the control group (p<0.001). Overall, the results suggest the presence of a potential inverse correlation between serum 25-hydroxy vitamin D levels and hypertension. The association analysis conducted indicated that there is no significant association between TaqI and bsmI genotypic variants and the risk of developing hypertension. However, it was observed that VDR gene polymorphisms do have a clear association with hypertension susceptibility, as evidenced by the significantly higher occurrence of FokI genotypic variants in hypertensive patients. Our study therefore introduces the possibility of utilizing 25-hydroxy vitamin D deficiency and VDR gene polymorphisms as a biomarker for hypertension.

22 February 2022 in Molecular and Cellular Endocrinology
Verified
Journal Article
Closed access
STSonia Tamanna
Sonia Tamanna
SMSaije K. Morosin
Saije K. Morosin
SDSarah J. Delforce
Sarah J. Delforce
DHDirk F. van Helden
Dirk F. van Helden
ELEugenie R. Lumbers
Eugenie R. Lumbers
KPKirsty G Pringle
Kirsty G Pringle

2 May 2024 in Journal of Molecular Graphics and Modelling
Verified
Journal Article
Closed access
IBimren Bayıl
imren Bayıl
SHSarowar Hossain
Sarowar Hossain
STSonia Tamanna
Sonia Tamanna
MUMd Jamir Uddin
Md Jamir Uddin
FAF.M. Mashood Ahamed
F.M. Mashood Ahamed
TTTugba Taskin Tok
Tugba Taskin Tok

19 February 2026 in Biochemistry and Biophysics Reports
Verified
Journal Article
Open access
NNNurun Nahar Nila
Nurun Nahar Nila
IMIsrat Dilruba Mishu
Israt Dilruba Mishu
ZMZimam Mahmud
Zimam Mahmud
STSonia Tamanna
Sonia Tamanna
KFKaniz Fahima
Kaniz Fahima
ZHZakir Hossain Howlader
Zakir Hossain Howlader
Aldo-keto reductase family 1 member C1 (AKR1C1) is a key enzyme involved in steroid hormone and xenobiotic metabolism and has been implicated in hormone-dependent cancers, chemoresistance, and inflammatory disorders. Genetic variation in AKR1C1 may influence enzyme structure and regulatory properties. In this study, we conducted a comprehensive in silico analysis to identify and characterize potentially deleterious nonsynonymous, non-coding, and cancer-associated single nucleotide polymorphisms (SNPs) in the human AKR1C1 gene. Missense, 3′-UTR, 5′-UTR, and intronic variants were systematically screened using multiple computational tools to evaluate their predicted functional, structural, and regulatory effects, incorporating residue conservation, domain mapping, post-translational modification sites, protein stability predictions, mutation clustering, and secondary and three-dimensional structural analyses. Among 301 missense variants analyzed, G20R and G62R were consistently prioritized as the most deleterious based on concordant predictions from 12 tools. Structural modeling suggested destabilization near the catalytic region, while conservation analysis indicated potential disruption of functionally important residues. Molecular dynamics simulations (200 ns) revealed minimal differences in overall structural deviation, flexibility, compactness, and solvent accessibility between the mutant and wild-type proteins, suggesting localized structural perturbations rather than widespread conformational instability. Analysis of non-coding variants identified several SNPs, including rs1163624611, rs1169939032, and rs1329563998, with predicted regulatory effects, and five 3′-UTR SNPs with potential to alter miRNA binding. From cBioPortal, 57 cancer-associated variants were retrieved, of which 43 unique missense SNPs remained after removing duplicates and synonymous or noncoding entries. Among these, 12 variants were classified as highly deleterious, including three predicted to affect post-translational modification sites. All were classified as passenger mutations, with Y55C and Y110H showing the strongest predicted structural impact. Overall, this comprehensive computational analysis highlights previously uncharacterized deleterious coding and regulatory variants of AKR1C1 with potential relevance to disease susceptibility and cancer progression. These findings provide a valuable framework for future experimental validation and risk assessment studies involving AKR1C1.

18 March 2025
Verified
Book Chapter
Closed access
STSonia Tamanna
Sonia Tamanna
TJTaslimul Jannat
Taslimul Jannat
AAAnass M. Abbas
Anass M. Abbas